Johnson & Johnson

News

CAR-T earlier use backing in multiple myeloma

CAR-Ts set to move earlier in multiple myeloma therapy

FDA advisors have said that two BCMA-targeted CAR-T therapies can be used earlier in the treatment pathway for multiple myeloma, setting up FDA approvals for use in a broa

News

AAD: J&J’s oral IL-23 drug shows durability in psoriasis

Patients with plaque psoriasis treated with Johnson & Johnson’s oral IL-23 inhibitor JNJ-2113 have been shown to maintain skin clearance for up to a year, pointing to a durable ef

News

In U-turn, NICE backs first drug for AL amyloidosis

Almost four years after it was approved in Europe to treat the incurable rare disease systemic amyloid light-chain (AL) amyloidosis, Johnson & Johnson’s Darzalex has b

News

Regeneron set for August FDA decision on BCMA bispecific

Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its lin

News

Tagrisso-chemo cleared in US as 1st-line lung cancer therapy

AstraZeneca’s Tagrisso can be used alongside chemotherapy as a frontline therapy for EGFR-positive non-small cell lung cancer (NSCLC), according to the FDA, consolidating

News

Pharma CEOs may be subpoenaed as IRA dispute rumbles on

US Senator Bernie Sanders has said he plans to hold a vote on 31st January to subpoena the chief executives of Johnson & Johnson and Merck & Co for a hearing on dr

CAR-Ts set to move earlier in multiple myeloma therapy

AAD: J&J’s oral IL-23 drug shows durability in psoriasis

In U-turn, NICE backs first drug for AL amyloidosis

Regeneron set for August FDA decision on BCMA bispecific

Tagrisso-chemo cleared in US as 1st-line lung cancer therapy

Pharma CEOs may be subpoenaed as IRA dispute rumbles on

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Johnson & Johnson

Editor's Picks